Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Roche Returns To RNAi With Santaris Buyout, While Biogen Re-Ups With Regulus

Executive Summary

Bristol will team with start-up financier Allied Minds to convert academic research into clinical candidates, with the pharma getting a license to acquire any backed entity that reaches preclinical stage. Two European firms, Boehringer Ingelheim and Medivir, partner again roughly a decade after a disappointing tie-up in HIV.

Advertisement

Related Content

U.K. Biotech Learns Lessons From History, Says BIA Head
Medivir Narrows Research Strategy To Cancer And Infectious Diseases
Santaris Acquisition By Roche May Help VCs Back New Biotechs In Europe
Deal Watch: Genentech Pays Big For Seragon’s Early Assets
Roche's Transfer Of Assets To Arrowhead May Create Most-Comprehensive RNAi Firm
Starlight Success: Isis, Alnylam Form Regulus To Develop MicroRNA Antagonists

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS056313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel